Recorded on Thursday 28 September 2023, ValiRx CEO Dr Suzanne Dilly and Chairman Dr Kevin Cox sat down for a Q&A session to answer some of our shareholder's questions.
We received a number of questions and both took the time to run through their questions, touching upon the successful launch event for Inaphaea BioLabs at their premises in MediCity, Nottingham.
During the Q&A session, Suzanne and Kevin answered questions concerning:
- VAL201 and a progress update
- An update on VAL301 and the reciprocal benefits
- VAL401's intensive business development programme
- ValiRx's core objectives and progress working with Dr Cathy Tralau-Stewart
- The development of our business model
- Inaphaea's progress so far and what it means for ValiRx
Click to watch the video stream: